RELERT

USDailyMed:Eletriptan AU:B1 N02CC06(WHO) AU:S3(Pharmacist only) & S4CA:℞-onlyUK:POM(Prescription only)US:℞-onlyIn general: ℞ (Prescription only) 3-{[(2R)-1-methylpyrrolidin-2-yl]methyl}-5-[2-(benzenesulfonyl)ethyl]-1H-indole 143322-58-1YHBr:177834-92-3Y 77993HBr:656631 40 DB00216YHBr:DBSALT000884Y 70379YHBr:570985Y 22QOO9B8KIHBr:M41W832TA3Y D07887YHBr:D01973Y CHEBI:5092​​​‍​​‍​​​​‍​​‍‍2YHBr:CHEBI:61176Y ChEMBL1510YHBr:ChEMBL1201003Y DTXSID9046861 Interactive image CN1CCC[C@@H]1Cc3c[nH]c4ccc(CCS(=O)(=O)c2ccccc2)cc34 InChI=1S/C22H26N2O2S/c1-24-12-5-6-19(24)15-18-16-23-22-10-9-17(14-21(18)22)11-13-27(25,26)20-7-3-2-4-8-20/h2-4,7-10,14,16,19,23H,5-6,11-13,15H2,1H3/t19-/m1/s1YKey:PWVXXGRKLHYWKM-LJQANCHMSA-NY Eletriptan, sold under the brand nameRelpaxand used in the form of eletriptan hydrobromide, is a second-generationtriptanmedicationintended for treatment ofmigraineheadaches.It is used as anabortive medication, blocking a migraine attack which is already in progress.Eletriptan is marketed and manufactured byPfizer. Eletriptan is a therapeutic alternative on theWorld Health Organization's List of Essential Medicines.